FOXO4-DRI for Sale: 10 mg Printed, 8.30 mg Measured

What FOXO4-DRI for sale actually gets you

The market has settled on one format: a 10 mg vial of lyophilised powder under a crimped seal, with a certificate and a research-use designation. There is no 5 mg or 30 mg tier, which removes the per-milligram optimisation that usually exists between vial sizes.

Below that standard, treat two things as warnings. Blends pairing FOXO4-DRI with other compounds make any single ingredient's contribution impossible to isolate and the certificate much harder to read. Pre-reconstituted solution or pre-loaded devices are worse: peptides are freeze-dried precisely because degradation accelerates in solution, so a supplier shipping it wet has either not considered stability or is relying on you not to.

You will also meet the phrase "pharma grade". There is no approved pharmaceutical version of this compound in any market, so there is no pharmaceutical grade to meet. Here it is decoration.

Which listing claims a document can actually settle

Take each claim a product page makes and ask what could possibly support it.

Claim	What would support it	Settles a number?
99%+ purity	An HPLC chromatogram tied to your lot	Composition, not quantity
10 mg per vial	A measured net content figure	Yes, and it is rarely given
Third-party tested	A named laboratory with an address	Only if the lab is named
Verified identity	Mass spectrometry confirming the molecule	Identity, not amount
Endotoxin free	An LAL screen on your specific batch	Per batch only
Pharma grade	Nothing. No approved product exists	No

Purity is the claim made most often; quantity is the claim assumed most often and measured least often. A listing can be entirely truthful about purity while leaving the amount you receive to the label.

The fill figures, and what they do to per-mg cost

Kovera Labs certified batch 55-05260628 at 99.411% purity with net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 at 99.97% purity with net content of 8.30 mg. Both vials were labelled 10 mg.

Batch	Purity	Net content	Cost per mg at $67.00
55-05260628 (Kovera)	99.411%	11.41 mg	$5.87
Label assumption	—	10 mg	$6.70
55-01260229 (MZ Biolabs)	99.97%	8.30 mg	$8.07

A 37% spread in delivered peptide sitting behind two excellent purity figures. That is the practical case for reading the certificate for your own lot rather than the one linked from the product page, which is not always the batch that ships.

What you are buying, chemically

FOXO4-DRI is a synthetic peptide. DRI stands for D-retro-inverso: it is built from D-amino acids, the mirror image of the form biology uses, assembled in reversed sequence. That construction presents a similar shape to the binding target while making the molecule far harder for proteases to degrade.

Its purpose is to disrupt the binding between the FOXO4 protein and p53 inside senescent cells, which is what keeps those cells alive despite their damage. Breaking it lets them undergo apoptosis while healthy cells are largely spared.

Reference data you can verify independently: PubChem CID 167312269, CAS 2460055-10-9, molecular formula C228H388N86O64, supplied as lyophilised powder. Listings sometimes spell it FOX04 with a digit zero; the compound is FOXO4, from Forkhead box protein O4, and the zero is a typo that spread into product URLs.

Frequently Asked Questions

What sizes of FOXO4-DRI are sold?expand_more

Effectively one, a 10 mg lyophilised vial. There is no larger format with a better per-milligram rate, so a listing offering unusual sizes warrants extra scrutiny rather than assumption of a better deal.

Does a 99% purity claim mean the vial holds 10 mg?expand_more

No. Purity is the proportion of present material that is the intended molecule; net content is how much material is present. The two published batches assayed 11.41 mg and 8.30 mg while both testing above 99% pure.

Why is pre-mixed FOXO4-DRI a red flag?expand_more

Peptides degrade faster in solution than as dry powder, which is why the market ships them lyophilised. A supplier offering pre-dissolved material is either indifferent to stability or selling something whose potency on arrival cannot be assumed.

What does pharma grade mean here?expand_more

Nothing. There is no approved pharmaceutical FOXO4-DRI in any market, so there is no pharmaceutical standard to meet and the phrase carries no regulatory weight.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

Epitalon dosage protocol

Epitalon (also Epithalon, Epithalamin tetrapeptide) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by Vladimir Khavinson by directed synthesis from the amino-acid composition of bovine pineal extract Epithalamin [1][2]. It is the most extensively studied of the Khavinson peptide bioregulators, with documented effects on telomerase activation, telomere elongation, melatonin restoration, and lifespan extension in rodent and Drosophila models [3][4][5]. Khavinson and colleagues showed Epitalon activates telomerase in human fetal somatic cell cultures with observable telomere elongation, and Anisimov demonstrated 12–13% lifespan extension in mice and 11–16% in fruit flies [6]. Standard research dosing is 5–10 mg subcutaneously per day for 10–20 consecutive days, repeated 2–3 times yearly. Epitalon is registered as a peptide bioregulator in Russia but is not approved by the FDA, EMA, or MHRA; outside Russia it is a research-only compound. Human clinical evidence is limited to Russian observational use in age-related disorders, with reports of restored circadian melatonin rhythms, improved immune markers, and normalized neuroendocrine function.

Open protocolarrow_forward

NAD dosage protocol

NAD+ (nicotinamide adenine dinucleotide) is the central redox and signaling cofactor for hundreds of enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38, with intracellular concentrations declining substantially with age across human tissues [1][2]. Sinclair, Imai, and colleagues established sirtuins as NAD-dependent deacetylases that regulate longevity, metabolism, and DNA repair, and showed that restoring NAD+ levels through precursor supplementation can reverse age-related metabolic decline in mice [3][4]. Yoshino and colleagues demonstrated in a randomized clinical trial that nicotinamide mononucleotide (NMN) at 250 mg/day improves muscle insulin sensitivity in prediabetic women [5]. NAD+ itself is administered as a research and integrative medicine intervention at 100–500 mg subcutaneously or intramuscularly, or 250–1000 mg by slow intravenous infusion over 1–4 hours, in cycles. NAD+ is sold as a supplement (oral, sublingual, injectable) but the FDA has not approved NAD+ injection for any therapeutic indication. NAD+ precursors (NR, NMN) have FDA NDI status as dietary supplements but are not approved drugs.

Open protocolarrow_forward

BPC-157 dosage protocol

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.

Open protocolarrow_forward

References & Citations

[1]
Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16.View source →
[2]
Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16(1):5672.View source →